Literature DB >> 30034992

Rapid-Acting Antidepressants: Mechanistic Insights and Future Directions.

Danielle M Gerhard1, Ronald S Duman1.   

Abstract

PURPOSE OF REVIEW: Ketamine produces rapid (within hours) antidepressant actions, even in patients considered treatment resistant, and even shows promise for suicidal ideation. Here, we review current research on the molecular and cellular mechanisms of ketamine and other novel rapid-acting antidepressants, and briefly explore gender differences in the pathophysiology and treatment of MDD. RECENT
FINDINGS: Ketamine, an NMDA receptor antagonist, increases BDNF release and synaptic connectivity, opposing the deficits caused by chronic stress and depression. Efforts are focused on the development of novel rapid agents that produce similar synaptic and rapid antidepressant actions, but without the side effects of ketamine. The impact of gender on the response to ketamine and other rapid-acting antidepressants is in early stages of investigation.
SUMMARY: The discovery that ketamine produces rapid therapeutic actions for depression and suicidal ideation represents a major breakthrough and much needed alternative to currently available medications. However, novel fast acting agents with fewer side effects are needed, as well as elucidation of the efficacy of these rapid-acting antidepressants for depression in women.

Entities:  

Keywords:  Antidepressants; BDNF; Depression; Ketamine; Sex differences

Year:  2018        PMID: 30034992      PMCID: PMC6051539     

Source DB:  PubMed          Journal:  Curr Behav Neurosci Rep


  91 in total

1.  Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.

Authors:  Madhukar H Trivedi; A John Rush; Stephen R Wisniewski; Andrew A Nierenberg; Diane Warden; Louise Ritz; Grayson Norquist; Robert H Howland; Barry Lebowitz; Patrick J McGrath; Kathy Shores-Wilson; Melanie M Biggs; G K Balasubramani; Maurizio Fava
Journal:  Am J Psychiatry       Date:  2006-01       Impact factor: 18.112

2.  Activity-Dependent Brain-Derived Neurotrophic Factor Release Is Required for the Rapid Antidepressant Actions of Scopolamine.

Authors:  Sriparna Ghosal; Eunyoung Bang; Wenzhu Yue; Brendan D Hare; Ashley E Lepack; Matthew J Girgenti; Ronald S Duman
Journal:  Biol Psychiatry       Date:  2017-06-23       Impact factor: 13.382

3.  Increase in Suicide in the United States, 1999-2014.

Authors:  Sally C Curtin; Margaret Warner; Holly Hedegaard
Journal:  NCHS Data Brief       Date:  2016-04

4.  Scopolamine produces larger antidepressant and antianxiety effects in women than in men.

Authors:  Maura L Furey; Ashish Khanna; Elana M Hoffman; Wayne C Drevets
Journal:  Neuropsychopharmacology       Date:  2010-08-25       Impact factor: 7.853

5.  BDNF Val66Met polymorphism is associated with higher anticipatory cortisol stress response, anxiety, and alcohol consumption in healthy adults.

Authors:  Lorenza S Colzato; A J Willem Van der Does; Coen Kouwenhoven; Bernet M Elzinga; Bernhard Hommel
Journal:  Psychoneuroendocrinology       Date:  2011-05-18       Impact factor: 4.905

6.  Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression.

Authors:  P V Choudary; M Molnar; S J Evans; H Tomita; J Z Li; M P Vawter; R M Myers; W E Bunney; H Akil; S J Watson; E G Jones
Journal:  Proc Natl Acad Sci U S A       Date:  2005-10-17       Impact factor: 11.205

Review 7.  Antidepressant effects of the muscarinic cholinergic receptor antagonist scopolamine: a review.

Authors:  Wayne C Drevets; Carlos A Zarate; Maura L Furey
Journal:  Biol Psychiatry       Date:  2012-11-28       Impact factor: 13.382

8.  Bidirectional Homeostatic Regulation of a Depression-Related Brain State by Gamma-Aminobutyric Acidergic Deficits and Ketamine Treatment.

Authors:  Zhen Ren; Horia Pribiag; Sarah J Jefferson; Matthew Shorey; Thomas Fuchs; David Stellwagen; Bernhard Luscher
Journal:  Biol Psychiatry       Date:  2016-02-13       Impact factor: 13.382

Review 9.  Bipolar and major depressive disorder: neuroimaging the developmental-degenerative divide.

Authors:  Jonathan Savitz; Wayne C Drevets
Journal:  Neurosci Biobehav Rev       Date:  2009-01-21       Impact factor: 8.989

10.  Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid receptors.

Authors:  Sungho Maeng; Carlos A Zarate; Jing Du; Robert J Schloesser; Joseph McCammon; Guang Chen; Husseini K Manji
Journal:  Biol Psychiatry       Date:  2007-07-23       Impact factor: 13.382

View more
  13 in total

1.  GABA interneurons are the cellular trigger for ketamine's rapid antidepressant actions.

Authors:  Danielle M Gerhard; Santosh Pothula; Rong-Jian Liu; Min Wu; Xiao-Yuan Li; Matthew J Girgenti; Seth R Taylor; Catharine H Duman; Eric Delpire; Marina Picciotto; Eric S Wohleb; Ronald S Duman
Journal:  J Clin Invest       Date:  2020-03-02       Impact factor: 14.808

Review 2.  Rodent ketamine depression-related research: Finding patterns in a literature of variability.

Authors:  Andrew J Polis; Paul J Fitzgerald; Pho J Hale; Brendon O Watson
Journal:  Behav Brain Res       Date:  2019-08-13       Impact factor: 3.332

Review 3.  Antidepressant effects of ketamine on depression-related phenotypes and dopamine dysfunction in rodent models of stress.

Authors:  Millie Rincón-Cortés; Anthony A Grace
Journal:  Behav Brain Res       Date:  2019-11-15       Impact factor: 3.332

Review 4.  In Vivo 13C Magnetic Resonance Spectroscopy for Assessing Brain Biochemistry in Health and Disease.

Authors:  Rimil Guha Roy; Avantika Samkaria; Pravat K Mandal; Joseph C Maroon; Yashika Arora
Journal:  Neurochem Res       Date:  2022-01-28       Impact factor: 3.996

5.  Cumulative Stress Burden on Motivated Action Revealed.

Authors:  Henry W Kietzman; Shannon L Gourley
Journal:  Biol Psychiatry       Date:  2020-10-01       Impact factor: 13.382

6.  The Effect of Acutely Administered Propofol on Forced Swim Test Outcomes in Mice.

Authors:  David G Daniel; Noah G Daniel; Donald T Daniel; Laura Copeland Flynn; Michael H Allen
Journal:  Innov Clin Neurosci       Date:  2019-09-01

7.  The Effect of Propofol on a Forced Swim Test in Mice at 24 Hours.

Authors:  David G Daniel; Noah G Daniel; Donald T Daniel; Laura Copeland Flynn; Michael H Allen
Journal:  Curr Ther Res Clin Exp       Date:  2020-06-14

8.  MicroRNA profiling identifies a novel compound with antidepressant properties.

Authors:  Stacy L Sell; Deborah R Boone; Harris A Weisz; Cesar Cardenas; Hannah E Willey; Ian J Bolding; Maria-Adelaide Micci; Michael T Falduto; Karen E O Torres; Douglas S DeWitt; Donald S Prough; Helen L Hellmich
Journal:  PLoS One       Date:  2019-08-23       Impact factor: 3.240

9.  5q35 duplication presents with psychiatric and undergrowth phenotypes mediated by NSD1 overexpression and mTOR signaling downregulation.

Authors:  Fabiola Quintero-Rivera; Celeste C Eno; Christine Sutanto; Kelly L Jones; Małgorzata J M Nowaczyk; Derek Wong; Dawn Earl; Ghayda Mirzaa; Anita Beck; Julian A Martinez-Agosto
Journal:  Hum Genet       Date:  2021-01-03       Impact factor: 4.132

10.  Novel Antidepressants in the Pipeline (Phase II and III): A Systematic Review of the US Clinical Trials Registry.

Authors:  Hitoshi Sakurai; Kengo Yonezawa; Hideaki Tani; Masaru Mimura; Michael Bauer; Hiroyuki Uchida
Journal:  Pharmacopsychiatry       Date:  2022-01-19       Impact factor: 2.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.